$2bn global coronavirus vaccine fund announced at Gavi summit
A $2bn procurement fund aimed at ensuring that
poorer countries can access doses of a potential coronavirus vaccine has been
announced at a virtual summit hosted by the UK.
The announcement was made at the third Gavi vaccine
alliance replenishment summit, a virtual pledging event that separately raised
$8.8bn, above the target of $7.4bn, for the private-public alliance’s general
work on immunising millions of people worldwide from longstanding diseases such
as measles.
The summit, the third replenishment summit since
Gavi was formed 20 years ago, took on an extra significance as world leaders
battle to set up a mechanism to ensure that any effective coronavirus vaccine
is produced at a scale possible to ensure it is not just distributed to the
countries that either can afford it or have invested in its research.
The worldwide scramble for masks and ventilators
that erupted in the early stages of the pandemic, when countries including
France requisitioned the nation’s entire supply of masks and the US apparently
paid off the shippers of loads already on airplanes to obtain ventilators, does
not bode well for global cooperation if and when a coronavirus vaccine becomes
available.
“Rich countries will most likely try to push their
way to the front of the queue, leaving poorer countries at the back, and that’s
a problem,” said Jimmy Whitworth, a professor of international public health at
the London School of Hygiene and Tropical Medicine. “I can’t imagine any
country saying, ‘Africa’s need is greater than ours, so they can get the
vaccine first and we’ll remain vulnerable.’”
The fund is modelled on previous work Gavi has done
with pneumococcal and Ebola vaccines. It is aiming to raise $2bn in the first
instance. Gavi said it had so far raised $567m of this target.
“By providing volume guarantees for specific
candidates before they are licenced, as well as market-wide guarantees, the
Gavi Covax AMC will encourage manufacturers to make investments in production
capacity,” Gavi said. “This in turn increases supply availability and reduces
the amount of time it takes for licenced vaccines to become available,
particularly to the poorest countries around the world.”
AstraZeneca announced it was the first vaccine
manufacturer to sign up to the Gavi Covax AMC. Under the terms of a $750
contract with Gavi, AstraZeneca will guarantee 300 million doses of the
Covid-19 vaccine that it is developing in collaboration with the University of
Oxford. These doses will be supplied on receiving a licence or prequalification
by the World Health Organisation, and are targeted for the end of the year.
AstraZeneca and Oxford said they had “committed to
operating on a not-for-profit basis for the duration of the coronavirus
pandemic period to enable broad and equitable access, including for low and
lower-middle income countries”.
In addition, AstraZeneca reached a licensing
agreement with the Serum Institute of India to supply one billion doses for low-
and middle-income countries.
Bill Gates, speaking at the virtual summit, said he
was impressed by the way in which the big pharmaceutical companies are
cooperating to ensure that a vaccine will be ready quickly. He told reporters
the companies have offered to make their manufacturing plants available to
produce a vaccine even if the vaccine selected for distribution by the WHO is
not their own.
His foundation announced it was putting up $1.6bn
over the next five years for Gavi’s continued core vaccine work, rivalling the
other lead nation state donors, the US, the UK and Norway.
Gates stressed Gavi cannot abandon its core vaccine
work in pursuit of a coronavirus vaccine. He said: “It is a unique time in
history. Never have so many people been aware of the importance of vaccines. As
we race to develop the coronavirus vaccine, we must renew our commitment to
delivering every life-saving vaccine there is to every child on earth”.
The UK prime minister, Boris Johnson, said: “The
world was coming together in the greatest shared endeavour of our lifetimes –
the triumph of humanity over disease.”
Gayle Smith, president of the ONE campaign that aims
to end extreme poverty and preventable disease, said: “Real credit goes to all
those who saw the bigger picture today, especially the UK for hosting this
event and to all those donors who stepped up and made sure Gavi is fully
funded. This is great leadership which will not only save millions of
children’s lives but increases our ability to prevent future pandemics –
protecting everyone.”




